Gilead Sciences is financially strong, but investors should treat its health as concentrated rather than risk-free In 2025, revenue rose to $294B, net income rose to $85B from $480M in 2024, and diluted EPS reached $678 Liquidity remains solid with $86B cash and marketable debt securities after $28B in debt repayments and $1B in dividends The key takeaway is that profitability and funding capacity are strong, while HIV dependence and 2026 cash use require monitoring
Financial Health Snapshot
What do Gilead Sciences latest financial metrics show?
Strong. The strongest factor is sharply higher 2025 earnings and cash, while the main concern is weaker Q1 2026 growth and high HIV concentration.
The latest verified fiscal period is 2025, with quarterly context through 2026-03-31. This verdict blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency, so it reflects both annual strength and the softer near-term operating trend.
For deeper reading, Gilead Sciences, Inc. (GILD): History, Ownership, Mission, How It Works & Makes Money can help place these metrics in a broader business context; among these four, revenue growth deserves deeper analysis first.
Revenue and Earnings Quality
How durable are Gilead Sciences revenue and earnings?
Mixed. Gilead Sciences showed strong annual profit confirmation in 2025, but the clearest divergence is that revenue remains highly concentrated in HIV while 2026-03-31 showed pressure across revenue, operating income, net income, and EPS.
Gilead Sciences looks stronger on earnings quality than on revenue breadth. Investors compare durable revenue with operating income, net income, and diluted EPS across matching annual periods because real quality shows up when sales growth also lifts profit and per-share results, not just the top line.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $294B, up 211%, 2025 | $480M, 2024 | Organic and product-driven, with HIV sales doing most of the work | The growth looks repeatable if the HIV franchise holds, but it is concentrated |
| Operating Income | $259B, 2026-03-31 | $299B, 2025-12-31 | Grew slower than revenue and then softened sequentially | Margins confirm some scale, but the latest quarter shows less momentum |
| Net Income | $202B, 2026-03-31 | $218B, 2025-12-31 | Supported by operating performance, with no unusual-item detail supplied | Final earnings still confirm profitability, but the trend is weaker than 2025 |
| Diluted EPS | $161, 2026-03-31 | $174, 2025-12-31 | Per-share results declined, so share count did not improve the story | Shareholders saw softer per-share growth than the annual earnings surge implied |
How durable is Gilead Sciences revenue?
The strongest durability signal is HIV, especially Biktarvy, but the biggest limitation is concentration: HIV made up 7075% of annual revenue, and Veklury is falling as COVID demand fades.
- Demand Quality: HIV demand is recurring and treatment-based, while Yeztugo and Biktarvy improve visibility. The HIV franchise also supports the link to Exploring Gilead Sciences, Inc. (GILD) Investor Profile: Who's Buying and Why?.
- Pricing and Volume: The split between price, volume, and mix was not fully provided. Biktarvy sales growth suggests strong volume and mix support, but the exact breakdown is unavailable.
- Diversification: HIV dominates, while Trodelvy, Livdelzi, and Hepcludex add some spread. Veklury remains a weak diversifier because pandemic-linked revenue is fading.
That mix matters because durable profits depend on whether Gilead Sciences can turn concentrated sales into steady cash conversion.
Profitability and Cash
How profitable and cash-generative is Gilead Sciences?
Gilead Sciences remained profitable, but the latest quarter showed weaker cash generation: accounting earnings were positive, while operating cash flow and free cash flow momentum were negative versus the comparable period.
For students comparing profit and cash, Gilead Sciences shows why net income and cash flow are not the same. Gross margin, operating margin, and net margin measure profit at different income-statement stages, while operating cash flow depends on cash collected and paid. See Gilead Sciences, Inc. (GILD): History, Ownership, Mission, How It Works & Makes Money for the business context.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Not provided in supplied data for 2026-03-31. | Not provided in supplied data for the prior compatible period. | Gross profit was $552B on revenue of $696B, but no verified margin percentage was supplied. | Product economics look profitable, but the margin rate itself cannot be confirmed from the provided data. |
| Operating Margin | Not provided in supplied data for 2026-03-31. | Not provided in supplied data for the prior compatible period. | Operating income was $259B after $293B of operating expenses, including $137B in R&D and $145B in SG&A. | Scale is producing operating profit, but the exact efficiency trend cannot be measured here. |
| Net Margin | Not provided in supplied data for 2026-03-31. | Not provided in supplied data for the prior compatible period. | Net income was $202B, with $24,000M of interest expense and $55,900M of income tax expense. | Final profitability is positive, so operations are still generating accounting earnings after financing and taxes. |
| Operating Cash Flow | Growth of -2351% for 2026-03-31. | Previous compatible value not supplied. | Negative growth versus the comparable period signals weaker cash conversion, but no dollar amount was provided. | Reported earnings are not fully confirmed by operating cash momentum. |
| Free Cash Flow | Growth of -2224% for 2026-03-31. | Previous supplied value not available. | Cash and marketable debt securities fell to $86B from $106B after $28B in debt repayments and $1B in dividends. | After capital returns and debt paydown, reinvestment flexibility depends on cash flow, not just net income. |
What most affects Gilead Sciences' cash conversion?
The biggest verified factor is the sharp drop in operating cash flow and free cash flow growth, alongside heavy cash use for $28B in debt repayments and $1B in dividends.
- Main Driver: Cash deployment was heavy and looks more structural for capital allocation than temporary.
- Evidence Gap: The supplied data does not show working-capital detail or capital expenditures.
- Metric to Monitor: Track operating cash flow and free cash flow in the next quarter.
Balance Sheet Strength
Does Gilead Sciences, Inc. have a strong balance sheet and liquidity?
Strong overall, with a large cash buffer after debt repayment. The main protection is $86B in cash and marketable debt securities at March 31, 2026; the main financing concern is still the material debt load, since maturity detail is not supplied.
Cash alone does not settle the question. The full picture depends on current assets, current liabilities, debt service, solvency, and refinancing flexibility, plus asset quality and how much room Gilead Sciences, Inc. has to fund operations, dividends, and investment without stress.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash And Cash Equivalents: $763B; Short Term Investments: $219B; Cash And Short Term Investments: $982B; Total Current Assets: $1864B; Total Current Liabilities: $948B. | Strong | Near-term obligations look covered without forcing an immediate liquidity squeeze. |
| Total and Net Debt | Short Term Debt: $131B; Long Term Debt: $2086B; Total Debt: $2217B; Net Debt: $1455B; Debt Growth: -983%. Prior-period Total Debt: $2459B; Net Debt: $1703B. | Mixed | Leverage is still meaningful even though debt declined from the prior period. |
| Debt Service and Refinancing | Interest Expense: $24000M; Net Interest Income: -$24000M. | Mixed | Ongoing interest burden matters, but supplied data do not support a maturity or refinance stress call. |
| Asset Quality | Total Assets: $5628B; Goodwill: $831B; Intangible Assets: $1638B; Goodwill And Intangible Assets: $2470B; Property Plant Equipment Net: $564B; Inventory: $191B; Net Receivables: $474B. | Mixed | Large acquired intangibles increase integration and valuation sensitivity, even though operating assets are still substantial. |
| Liabilities and Equity | Total Liabilities: $3285B; Total Stockholders Equity: $2352B; Total Equity: $2343B. | Strong | The equity base is large enough to absorb pressure, but liabilities remain substantial. |
Which balance-sheet risk matters most for Gilead Sciences, Inc.?
The biggest risk is leverage, not near-term liquidity. Gilead Sciences, Inc. has a strong cash base, but $2217B of total debt and no supplied maturity profile keep refinancing and interest burden on watch.
- Current Exposure: Total Debt: $2217B; Net Debt: $1455B.
- Protection: Cash And Short Term Investments: $982B and Total Current Assets: $1864B.
- Warning Signal: Watch whether debt keeps falling and whether interest expense stays manageable.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For related background, see Mission Statement, Vision, & Core Values (2026) of Gilead Sciences, Inc. (GILD).
Capital efficiency
How efficient is Gilead Sciences at reinvesting capital?
Mixed. Gilead Sciences appears able to fund reinvestment from internal cash generation, but recent negative cash-flow growth, heavy acquisition activity, and a $32B multi-year investment commitment make future capital efficiency dependent on execution.
Return measures need leverage, asset intensity, capex, working capital, and external funding context. For Gilead Sciences, the question is not just whether profits are high, but whether those profits can keep funding R&D, launches, acquisitions, manufacturing, dividends, and debt reduction without pressuring returns.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable from supplied inputs. | Operating profit quality cannot be verified directly, but profit generation and active reinvestment suggest the result depends on post-deal execution. | Investors should watch whether invested capital keeps producing operating value after acquisitions and pipeline spending. |
| ROE and ROA | Net Income 2025: $85B; Number Of Shares: 124B common stock outstanding on February 13, 2026; Weighted Average Shares Growth: 000% for 2026-03-31. | ROE and ROA cannot be calculated from the supplied data, but share count stability limits dilution concerns while asset and leverage effects remain unverified. | Shareholder return quality looks tied to earnings durability, not just leverage, while asset efficiency still needs confirmation. |
| Maintenance and Growth Investment | Research And Development Expenses: $137B for 2026-03-31; Rdexpense Growth: -1338%; Growth Capital Expenditure: 4293% for 2026-03-31; R&D expenses as a percentage of product sales are projected to remain below 20% for FY 2026. | R&D appears significant but still bounded relative to product sales; the capex figure is provided as growth intensity, not dollars, so the maintenance-growth split cannot be separated cleanly. | Gilead Sciences is reinvesting heavily enough to support future launches and manufacturing, but the intensity is rising unevenly across periods. |
| Internal Funding Capacity | Cash and Marketable Debt Securities: $86B at March 31, 2026; Operating Cash Flow Growth: -2351%; Free Cash Flow Growth: -2224%; Arcellx completed for $78B, Tubulis announced for $315B upfront, and Ouro Medicines completed for $217B. | Internal funding looks available now, but the recent cash-flow decline and acquisition commitments raise the risk that future reinvestment becomes partly externally funded or more cash constrained. | That can affect leverage, flexibility, and shareholder returns, especially if integration takes longer than expected. |
Are Gilead Sciences’s returns on capital sustainable?
Probably, but only if operating cash stays strong. The biggest durability support is profit generation from its core business, while the main threat is the cash burden from acquisitions, pipeline integration, and the Mission Statement, Vision, & Core Values (2026) of Gilead Sciences, Inc. (GILD) linked to broader strategic execution.
- Operating Source: Profit generation and R&D kept below 20% of product sales support reinvestment capacity.
- Funding Requirement: The largest verified need is the $32B multi-year investment commitment through 2030, plus acquisition integration.
- Durability Test: Returns weaken if Operating Cash Flow Growth and Free Cash Flow Growth stay negative while capital spending and deal costs rise.
Liquidity Check
How resilient is Gilead Sciences, and which warning signs matter most?
Resilience is Mixed. The main buffer is still-profitable operations with strong cash generation, lower total debt of $2217B, and raised FY 2026 revenue guidance of $30B–$304B. The most important verified warning sign is HIV concentration, which keeps results sensitive to pricing, access, competition, and launch execution.
Gilead Sciences can still fund essential investment, but resilience is not bulletproof if revenue mix, policy pressure, and cash flow weaken at the same time. The cash and marketable debt securities balance fell to $86B from $106B after $28B in debt repayments and $1B in dividends, so Exploring Gilead Sciences, Inc. (GILD) Investor Profile: Who's Buying and Why? depends on continued operating strength.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | HIV concentration can magnify pricing, access, and competition pressure on earnings, cash flow, and debt capacity if the mix shifts sharply. | Biktarvy patent protection settlement agreements extending protection to 2036, Yeztugo approval for twice-yearly HIV-1 PrEP, and BIC/LEN review with a PDUFA date of August 27, 2026. | HIV product sales as a percentage of total annual revenue moving higher or Biktarvy growth slowing materially. |
| Working-Capital or Investment Pressure | Policy pressure and lower cash balances can absorb flexibility needed for R&D, launches, and pipeline scale-up. | Still-profitable operations, Net Income of $202B for 2026-03-31, and FY 2026 revenue guidance raised by $400M. | Operating cash flow or free cash flow turning more negative, or cash and marketable debt securities falling further. |
| Interest or Refinancing Pressure | Interest expense reduces free cash flow and leaves less room if funding conditions tighten. | Total Debt decline to $2217B and cash reserves of $86B help support financing flexibility. | Interest Expense of $24000M staying elevated or net interest income remaining at -$24000M. |
Which financial warning signs should investors monitor at Gilead Sciences?
The top two signals are HIV revenue concentration and cash-flow deterioration; both are confirmed risks now. A third is the 201% fiscal 2026 revenue headwind from the December 15, 2025 drug-pricing agreement and policy changes, which is more of a forward risk than current deterioration.
HIV concentration and product transition risk
HIV product sales reached $208B, so the mix is highly exposed to pricing, access, and competitive shifts. The buffer is Biktarvy growth and launch execution, but the next metric is HIV product sales as a percentage of total annual revenue.
Cash flow weakness after policy pressure
Q1 2026 Operating Cash Flow Growth was -2351% and Free Cash Flow Growth was -2224%, which is real deterioration. The buffer is continued profitability, and the next metric to watch is whether operating cash flow recovers as guidance is executed.
Veklury decline reduces diversification
Veklury sales were $911M, a 4966% year-over-year decline as COVID-19 hospitalization rates fell. That matters because the revenue base relies more on HIV and newer franchises, so investors should monitor non-HIV product sales growth by franchise.
Overall Scorecard
What does Gilead Sciences' financial health mean for investors?
Gilead Sciences’ overall financial health is strong, with profitability and liquidity as the best supports. The weakest factor is revenue concentration, and the most important condition for the investment case is whether cash flow stays strong enough to fund launches, R&D, dividends, and debt service.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | 2025 Total Revenue was $294B, and FY 2026 Revenue Guidance was raised to $30B–$304B, but Revenue Growth was -1217% in 2026-03-31 and HIV product sales were 7075% of annual revenue. |
| Profitability and Cash | Strong | Net Income 2025 was $85B, Diluted EPS 2025 was $678, and Net Income was $202B for 2026-03-31, but Operating Cash Flow Growth was -2351% and Free Cash Flow Growth was -2224%. |
| Balance Sheet and Liquidity | Strong | Cash and Marketable Debt Securities were $86B after $28B in debt repayments and $1B in dividends, and FMP Cash And Short Term Investments were $982B at 2026-03-31, though Total Debt of $2217B still matters. |
| Capital Efficiency | Mixed | R&D expenses as a percentage of product sales are projected below 20% for FY 2026, but recent acquisitions of $78B, $315B upfront, and $217B raise integration and return-on-capital questions. |
| Financial Resilience | Mixed | Biktarvy patent protection to 2036, Yeztugo approval, Trodelvy growth, Livdelzi progress, and Hepcludex approval help diversification, while Veklury sales declined 4966% and a 201% 2026 revenue headwind pressures the base. |
- What Supports the Thesis: Strong annual profit, large liquidity, and debt repayment give Gilead Sciences room to fund R&D, launches, and dividends.
- What Challenges the Thesis: HIV concentration and weak cash-flow momentum create uncertainty about how fast newer products can broaden the base.
- What to Monitor: Cash And Short Term Investments, Free Cash Flow Growth, HIV product sales as a percentage of total annual revenue. For mission context, see Mission Statement, Vision, & Core Values (2026) of Gilead Sciences, Inc. (GILD).
Forecasts, scenario work, and valuation models should stress whether earnings strength can keep supporting growth, liquidity, and reinvestment if revenue mix shifts or cash conversion weakens.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
How much cash remains after debt payments?
Gilead reported Cash and Marketable Debt Securities of $86B at March 31, 2026, down from $106B on December 31, 2025 The decline followed $28B in debt repayments and $1B in dividends
Why did Gilead net income surge in 2025?
Net Income 2025 was $85B, rising from $480M in 2024 The financial-health analysis should show that improvement, but it should not assign a specific cause unless supported by disclosed income statement detail, acquisition effects, or unusual items
What does HIV concentration mean for resilience?
HIV product sales reached $208B, representing 7075% of total annual revenue That supports scale and visibility, especially with Biktarvy, but it also means pricing, access, competition, and product-cycle risks can have outsized financial effects
Can Gilead keep funding dividends internally?
Gilead paid $1B in dividends before March 31, 2026 and set a quarterly payment of $082 per share Investors should compare future dividends with operating cash flow and free cash flow, not just net income
Is Gilead carrying too much debt now?
FMP data show Total Debt of $2217B and Net Debt of $1455B at 2026-03-31 Debt declined from Total Debt of $2459B at 2025-12-31, but maturities, rates, and coverage ratios were not supplied